$25.47 Million in Sales Expected for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) This Quarter

Brokerages expect Xeris Biopharma Holdings, Inc. (NASDAQ:XERSGet Rating) to report $25.47 million in sales for the current quarter, according to Zacks. Four analysts have made estimates for Xeris Biopharma’s earnings, with the lowest sales estimate coming in at $24.69 million and the highest estimate coming in at $27.20 million. Xeris Biopharma reported sales of $8.84 million during the same quarter last year, which would suggest a positive year over year growth rate of 188.1%. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Xeris Biopharma will report full year sales of $109.97 million for the current fiscal year, with estimates ranging from $103.00 million to $117.90 million. For the next financial year, analysts anticipate that the business will post sales of $158.63 million, with estimates ranging from $136.00 million to $192.40 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Xeris Biopharma.

Xeris Biopharma (NASDAQ:XERSGet Rating) last announced its quarterly earnings results on Thursday, March 10th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.21). The firm had revenue of $21.43 million for the quarter, compared to analyst estimates of $20.72 million. Xeris Biopharma had a negative net margin of 217.81% and a negative return on equity of 359.97%. During the same period in the previous year, the firm posted ($0.41) EPS.

Several research analysts have recently weighed in on XERS shares. SVB Leerink lowered their price target on shares of Xeris Biopharma from $8.00 to $6.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 16th. Craig Hallum assumed coverage on shares of Xeris Biopharma in a research report on Thursday, April 28th. They issued a “buy” rating and a $6.50 target price on the stock. Zacks Investment Research cut shares of Xeris Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, January 20th. Mizuho decreased their target price on shares of Xeris Biopharma from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, March 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price (down previously from $8.00) on shares of Xeris Biopharma in a research report on Friday, March 11th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $6.13.

In other news, insider Steven Prestrelski sold 11,228 shares of the stock in a transaction dated Tuesday, February 22nd. The shares were sold at an average price of $2.42, for a total transaction of $27,171.76. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Paul R. Edick purchased 100,000 shares of Xeris Biopharma stock in a transaction dated Thursday, May 12th. The shares were acquired at an average cost of $1.40 per share, for a total transaction of $140,000.00. Following the transaction, the insider now directly owns 1,508,064 shares of the company’s stock, valued at approximately $2,111,289.60. The disclosure for this purchase can be found here. 4.01% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its stake in shares of Xeris Biopharma by 218.5% during the first quarter. Goldman Sachs Group Inc. now owns 725,255 shares of the company’s stock worth $1,857,000 after buying an additional 497,564 shares during the period. State Street Corp increased its stake in shares of Xeris Biopharma by 5.0% during the first quarter. State Street Corp now owns 384,761 shares of the company’s stock worth $985,000 after buying an additional 18,252 shares during the period. UBS Group AG increased its stake in shares of Xeris Biopharma by 298.6% during the first quarter. UBS Group AG now owns 50,351 shares of the company’s stock worth $129,000 after buying an additional 37,719 shares during the period. Northern Trust Corp increased its stake in shares of Xeris Biopharma by 8.6% during the first quarter. Northern Trust Corp now owns 206,448 shares of the company’s stock worth $529,000 after buying an additional 16,426 shares during the period. Finally, Ergoteles LLC purchased a new stake in shares of Xeris Biopharma during the first quarter worth approximately $65,000. Hedge funds and other institutional investors own 18.72% of the company’s stock.

Shares of XERS stock opened at $2.21 on Tuesday. The company’s 50-day moving average price is $2.45 and its 200-day moving average price is $2.34. The company has a current ratio of 1.80, a quick ratio of 1.57 and a debt-to-equity ratio of 0.92. The stock has a market cap of $146.96 million and a price-to-earnings ratio of -1.50. Xeris Biopharma has a twelve month low of $1.25 and a twelve month high of $4.98.

Xeris Biopharma Company Profile (Get Rating)

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Featured Articles

Get a free copy of the Zacks research report on Xeris Biopharma (XERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xeris Biopharma (NASDAQ:XERS)

Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.